An Ex Vivo Evaluation of Moxifloxacin Nanostructured Lipid Carrier Enriched In Situ Gel for Transcorneal Permeation on Goat Cornea.
Administration, Ophthalmic
Alginates
/ chemistry
Animals
Anti-Bacterial Agents
/ administration & dosage
Calorimetry, Differential Scanning
Cornea
/ metabolism
Drug Carriers
/ chemistry
Drug Liberation
Drug Stability
Endophthalmitis
/ drug therapy
Gels
Goats
Humans
Hypromellose Derivatives
/ chemistry
Lipids
/ chemistry
Microbial Sensitivity Tests
Moxifloxacin
/ administration & dosage
Nanoparticles
/ chemistry
Permeability
Staphylococcus aureus
/ drug effects
X-Ray Diffraction
drug delivery system(s)
factorial design
lipid nanoparticle(s) (LNP)
nanoparticle(s)
ophthalmic drug delivery
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
21
11
2018
revised:
04
03
2019
accepted:
02
04
2019
pubmed:
13
4
2019
medline:
22
8
2020
entrez:
13
4
2019
Statut:
ppublish
Résumé
The study was designed to fabricate the moxifloxacin nanostructured lipid carriers (MOX-NLCs) loaded in situ gel for opthalmic application to improve the corneal permeation and retention and also subside the toxic effect associated with intracameral injection of moxifloxacin in endophthalmitis treatment. Initially, Box-Behnken design was used to optimize the various factors significantly affecting the final formulation attributes. MOX-NLCs with particle size 232.1 ± 9.2 nm, polydispersity index 0.247 ± 0.031, zeta potential -16.3 ± 1.6 mV, entrapment efficiency 63.1 ± 2.4%, and spherical shape was achieved. The optimized MOX-NLCs demonstrated the Higuchi release kinetics with highest regression coefficient. Besides this, FTIR, differential scanning calorimetry, and X-ray diffraction results suggested that MOX had excellent compatibility with excipients. Furthermore, the results of ex-vivo permeation study demonstrated 2-fold higher permeation (208.7 ± 17.6 μg), retention (37.26 ± 2.83 μg), and flux (9.57 ± 0.73 μg/cm
Identifiants
pubmed: 30978345
pii: S0022-3549(19)30228-X
doi: 10.1016/j.xphs.2019.04.005
pii:
doi:
Substances chimiques
Alginates
0
Anti-Bacterial Agents
0
Drug Carriers
0
Gels
0
Lipids
0
Hypromellose Derivatives
3NXW29V3WO
Moxifloxacin
U188XYD42P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2905-2916Informations de copyright
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.